Hormonal
GLP-1 receptor agonists (GLP-1RAs) activate brown adipose tissue (BAT) in humans, increasing its metabolic volume and glucose uptake, although this activation does not necessarily translate to increased fat fraction reduction or resting energy expenditure in all clinical contexts.
If you are using a GLP-1 medication like semaglutide or liraglutide, part of its benefit comes from activating your brown fat, which burns energy as heat. This happens alongside reduced appetite. While this doesn't always show up as 'less fat' in immediate scans, it contributes to better metabolic health and weight management. Stick with the treatment as prescribed.
exenatide increased the metabolic volume (+28%, p < 0.05) and mean standardized uptake value (SUVmean) (+11%, p < 0.05) of cervical and supraclavicular BAT depots... exenatide did not impact 18F-FDG uptake in the subcutaneous or visceral WAT depots... treatment with liraglutide for 26 weeks was not associated with fat fraction reduction... treatment with exenatide did not affect the fat fraction and volume in the total cohort.
Why this rating
Based on two small human clinical trials (n=50 and n=24) and extensive preclinical data; evidence is promising but limited by small sample sizes and conflicting MRI results.
Source
Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
Tim Hropot et al. · International Journal of Molecular Sciences · 2023
DOI 10.3390/ijms24108592
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →